Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.47 |
| ▸ | DPYD | Q12882 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eniluracil SCHEMBL1276303 | 0.86 | DPYD (0.65) | ATAD2DPYD | |
| SCHEMBL30847882 | 0.84 | ATAD2 (0.40) | ATAD2DPYD | |
| SCHEMBL29007135 | 0.81 | KMT2A (0.54) | — | |
| SCHEMBL11147060 | 0.81 | ATAD2 (0.44) | ATAD2 | |
| SCHEMBL4273200 | 0.81 | ATAD2 (0.44) | ATAD2 | |
| SCHEMBL30716110 | 0.80 | GAA (0.47) | ATAD2DPYD | |
| SCHEMBL17682900 | 0.79 | ATAD2 (0.42) | ATAD2DPYD | |
| SCHEMBL28009535 | 0.79 | LMNA (0.40) | ATAD2 | |
| SCHEMBL1144951 | 0.79 | ATAD2 (0.39) | ATAD2DPYD | |
| SCHEMBL161148 | 0.79 | ATAD2 (0.54) | ATAD2DPYD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| EP-1720890-B1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | LEUVEN K U RES & DEV (BE) | 2015-05-20 | — | — | EP | claimed |
| JP-4745329-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| JP-2007526048-A | — | — | 2007-09-13 | — | — | JP | claimed |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | claimed |
| EP-1750572-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | Stressmeter A/S (DK) | 2007-02-14 | — | — | EP | claimed |
| EP-1720890-A2 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.Leuven Research & Development (BE) | 2006-11-15 | — | — | EP | claimed |
| WO-2005084529-A2 | METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF | STRESSMETER A/S (DK) | 2005-09-15 | — | — | WO | claimed |
| WO-2005085268-A2 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-09-15 | — | — | WO | claimed |
| EP-4739351-A1 | GENE REPLACEMENT THERAPY FOR ALPK3 CARDIOMYOPATHY | The Regents of the University of California (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260085366-A1 | PSILOCYBE ASSAY | MEDICINAL GENOMICS CORP (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4587594-A1 | <SMALLCAPSILOCYBE ASSAY | Medicinal Genomics Corporation (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3710820-B1 | DEVICES FOR SAMPLE ANALYSIS USING EPITACHOPHORESIS | HOFFMANN LA ROCHE (CH) | 2025-06-11 | — | — | EP | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085366-A1 | PSILOCYBE ASSAY | RNGTT, MYCBP, SLTM | ATAD2 2455/4885DPYD 1434/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | ATAD2 3891/4885DPYD 2088/4885 |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | ENTPD5, PPA1, TYMP | ATAD2 2975/4885DPYD 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.